The role of the pathologist in breast cancer management

Cancer

Volumn 66, Issue 14 S, 1990, Pages 1363-1372

  Hutter, Robert V P ^a,b,c  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c College of Physicians and Surgeons of Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER THERAPY; CONFERENCE PAPER; FEMALE; HISTOLOGY; HUMAN; PATHOLOGIST; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; HUMAN; LYMPHATIC METASTASIS; PATHOLOGY; PHYSICIAN'S ROLE; PROGNOSIS; ROLE;

EID: 0025041679     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19900915)66:14+<1363::AID-CNCR2820661411>3.0.CO;2-4     Document Type: Article

References (72)

1. College of American Pathologists Patterns of Care Study Steering Committee. Patterns of Care Study: Improving cancer care by assuring the quality of pathology reports
2. The pathologist as a consultant in cancer patient management: A patterns of care study in pathology
3. Guidelines for data to be included in consultation reports on breast cancer bladder cancer, and Hodgkin's disease
4. American Joint Committee on Cancer
5. Fine needle aspiration cytology in the management of palpable benign and malignant breast disease: Correlation with clinical and mammographic findings
6. X‐ray guided fineneedle aspiration for the cytologic diagnosis of nonpalpable breast lesions
7. Stereotaxic fine needle aspiration cytology of clinically occult malignant and premalignant breast lesions
8. Atypia in fine‐needle aspiration cytology of the breast: a histologic follow‐up study of 301 cases
9. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 6) I. Intraductal carcinoma (DCIS)
10. Duct carcinoma in situ
11. Mammographically detected duct carcinoma in situ
12. The study of mammary carcinoma by mammography and whole organ sectioning: Early observations
13. Management and survival of female patients with “minimal” breast cancer: As observed in the long‐term and short‐term surveys of the American College of Surgeons
14. The influence of pathologic factors on breast cancer management
15. Pathologic types of breast cancer: their prognoses
16. Pathological parameters useful in predicting prognosis for patients with breast cancer.
17. Prognosis in carcinoma of the breast
18. Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed 15 years
19. Host resistance and survival in carcinoma of the breast: A study of 104 cases of medullary carcinoma in a series of 1141 cases of breast cancer followed for 20 years
20. Nuclear structure in cancer tissues
21. The pathologist's role in the diagnosis and treatment of invasive breast cancer
22. Interobserver reproducibility of histopathological features in stage II breast cancer: An ECOG study
23. Observer variation in the histological grading of rectal carcinoma
24. The histological grading of neoplasms
25. Inflammatory carcinoma of the breast
26. The prognostic value of blood vessel invasion and lymphocytic infiltrates in breast carcinoma
27. Prognostic significance of blood vessel invasion in carcinoma of the breast in women
28. Use of Ulex europaeus agglutinin I in the identification of lymphatic and blood vessel invasion in previously stained microscopic slides
29. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 6). II. Relation of local breast recurrence to multicentricity
30. The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy
31. Current concepts: Ductal carcinoma in situ (intraductal carcinoma) of the breast
32. Pathologic findings on re‐excision of the primary site in breast cancer patients considered for treatment by primary radiation therapy
33. Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy
34. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update
35. A long‐term follow‐up study of survival in stage I (T1 N0 M0) and stage II (T1 N1 M0) breast carcinoma
36. Increased lymph node metastases at mastectomy for breast cancer associated with host obesity cigarette smoking, age, and large tumor size
37. Adjuvant therapy of node‐negative breast cancer (editorial)
38. Breast cancer therapy: Exercising all our options (editorial)
39. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐negative tumors
40. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐positive tumors
41. Efficacy of adjuvant chemotherapy in high‐risk node‐negative breast cancer
42. The Ludwig Breast Cancer Study Group. Prolonged disease‐free survival after one course of perioperative adjuvant chemotherapy for node‐negative breast cancer
43. Immunohistologic detection of estrogen receptors in paraffin‐embedded breast cancers: Correlation with cytosol measurements
44. Immunostaining of estrogen receptor in paraffin sections of breast carcinomas using monoclonal antibody D75P3y: Effects of fixation
45. Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer
46. Immunocytochemical detection of estrogen and progesterone receptors in 124 human breast cancers
47. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S‐phase fraction
48. Detection of metastatic breast carcinoma with monoclonal antibodies to cytokeratins
49. Lymph node metastasis in carcinoma of the female mammary gland
50. Significance of occult metastases
51. Detection and significance of occult axillary node metastases in patients with invasive breast cancer
52. Significance of axillary macrometastasies and micrometastases in mammary cancer
53. Axillary micrometastases and micrometastases in carcinoma of the breast
54. Micrometastases to axillary lymph nodes from carcinoma of the breast: Detection by immunohistochemistry and prognostic significance
55. The value of bone marrow biopsy in breast cancer at time of diagnosis. A prospective study
56. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease
57. The fate of bone marrow micrometastases in patients with primary breast cancer
58. The value of morphometry to classic prognosticators in breast cancer
59. The multivariate prognostic index and nuclear DNA content are independent prognostic factors in primary breast cancer patients
60. Predictors of recurrence and survival of patients with breast cancer
61. Histologic features associated with long term survival in breast cancer
62. The significance of DNA measurements in a histologically defined subset of infiltrating ductal carcinomas of the breast with long‐term follow‐up
63. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer
64. Oncogene structure, function, and expression in breast cancer
65. Human breast cancer: correlation of relapse and survival with amplification of HEr‐2/neu oncogene
66. Studies of the HEr‐2/neu proto‐oncogene in human breast and ovarian cancer
67. Neu‐protein overexpression in breast cancer
68. In vivo amplification and rearrangement of c‐myc oncogene in human breast tumors
69. In situ c‐myc expression and genomic status of the c‐myc locus in infiltrating ductal carcinoma of the breast